INCY Earnings Date: Feb 9, 2027 (Estimated) — Incyte Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is INCY's next earnings date?
Incyte Corporation (INCY) is expected to report Q4 2026 earnings on Tuesday, February 9, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.90 on revenue of $1.53B.
How did INCY do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Incyte Corporation posted EPS of -$3.60 versus the -$3.93 estimate, a beat of 8.4%. Revenue was $1.56B against a $1.46B estimate. The stock's 1-day post-earnings move was -0.1%.
How much does INCY stock move after earnings?
INCY beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.1% (up or down) in the day after earnings.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
🤖 AI Earnings Analysis
Incyte’s Q3 headline beat was strong, with $1.6B revenue and $444M operating income, but reported EPS of -$3.60 versus $2.26 a year earlier makes growth figures unreliable without catalyst detail.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -3.93 | -3.60 | +8.40% | $1.56B | ✅ Beat | -0.06% | — | — |
| 2026-07-28 | Q2 2026 | 1.84 | 3.09 | +67.93% | $1.66B | ✅ Beat | +9.30% | -0.37% | +9.13% |
| 2026-04-28 | Q1 2026 | 1.31 | 1.81 | +38.17% | $1.27B | ✅ Beat | +2.12% | +1.49% | +1.70% |
| 2026-02-10 | Q4 2025 | 1.83 | 1.80 | -1.64% | $1.51B | ❌ Miss | -8.24% | -7.22% | -13.18% |
| 2025-10-28 | Q3 2025 | 1.53 | 2.26 | +47.71% | $1.37B | ✅ Beat | -1.54% | +9.12% | +13.40% |
| 2025-07-29 | Q2 2025 | 1.34 | 1.57 | +17.16% | $1.22B | ✅ Beat | +10.28% | +11.23% | +19.73% |
| 2025-04-29 | Q1 2025 | 1.03 | 1.16 | +12.62% | $1.05B | ✅ Beat | +1.53% | +4.35% | +9.09% |
| 2025-02-10 | Q4 2024 | 1.55 | 1.43 | -7.74% | $1.18B | ❌ Miss | -7.86% | -5.00% | -8.17% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $1.48B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| J A K A F I | 64.9% | $959.0M | +4.6% | $801.6M | $873.5M | $916.7M | $958.5M |
| OPZELURA | 17.3% | $254.9M | +35.6% | $118.7M | $164.5M | $188.0M | $207.3M |
| ZYNYZ | 3.9% | $58.3M | +157.2% | $3.0M | $8.9M | $22.7M | $31.7M |
| M I N J U V I | 3.7% | $54.6M | +30.1% | $29.6M | $31.1M | $42.0M | $41.9M |
| Milestone And Contract Revenue | 3.4% | $49.8M | +10.7% | — | $5.0M | $45.0M | $100.0M |
| Olumiant Royalty | 2.6% | $39.1M | +5.2% | $30.8M | $33.5M | $37.1M | $43.2M |
| I C L U S I G | 2.3% | $33.5M | -10.8% | $29.5M | $32.7M | $37.6M | $34.2M |
By region
Q3 FY26 · $1.54B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| U [S] | 93.0% | $1.43B | +13.8% | $981.6M | $1.13B | $1.26B | $1.42B |
| Europe | 7.0% | $107.4M | +7.0% | $68.6M | $78.8M | $100.3M | $76.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.